YARS1
Tyrosine--tRNA ligase, cytoplasmic
Also known as: SYYC_HUMAN, tyrRS, YARS, YRS, YTS
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P54577
- Gene
- YARS1
- Ensembl
- ENSG00000134684
- Chromosome
- 1
- Canonical length
- 528 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nuclear bodies,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Aminoacyl-tRNA synthetases catalyze the aminoacylation of tRNA by their cognate amino acid. Because of their central role in linking amino acids with nucleotide triplets contained in tRNAs, aminoacyl-tRNA synthetases are thought to be among the first proteins that appeared in evolution. Tyrosyl-tRNA synthetase belongs to the class I tRNA synthetase family. Cytokine activities have also been observed for the human tyrosyl-tRNA synthetase, after it is split into two parts, an N-terminal fragment that harbors the catalytic site and a C-terminal fragment found only in the mammalian enzyme. The N-terminal fragment is an interleukin-8-like cytokine, whereas the released C-terminal fragment is an EMAP II-like cytokine. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
528 residues, UniProt reviewed canonical sequence.
>P54577|YARS1
1 MGDAPSPEEK LHLITRNLQE VLGEEKLKEI LKERELKIYW GTATTGKPHV AYFVPMSKIA
61 DFLKAGCEVT ILFADLHAYL DNMKAPWELL ELRVSYYENV IKAMLESIGV PLEKLKFIKG
121 TDYQLSKEYT LDVYRLSSVV TQHDSKKAGA EVVKQVEHPL LSGLLYPGLQ ALDEEYLKVD
181 AQFGGIDQRK IFTFAEKYLP ALGYSKRVHL MNPMVPGLTG SKMSSSEEES KIDLLDRKED
241 VKKKLKKAFC EPGNVENNGV LSFIKHVLFP LKSEFVILRD EKWGGNKTYT AYVDLEKDFA
301 AEVVHPGDLK NSVEVALNKL LDPIREKFNT PALKKLASAA YPDPSKQKPM AKGPAKNSEP
361 EEVIPSRLDI RVGKIITVEK HPDADSLYVE KIDVGEAEPR TVVSGLVQFV PKEELQDRLV
421 VVLCNLKPQK MRGVESQGML LCASIEGINR QVEPLDPPAG SAPGEHVFVK GYEKGQPDEE
481 LKPKKKVFEK LQADFKISEE CIAQWKQTNF MTKLGSISCK SLKGGNISLocalizationUniProt · AlphaFold · HPA
Whether an antibody against YARS1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 80 nTPM
Expression across tissuesHPA
Tissue
- pancreas: 80 nTPM
- basal ganglia: 62 nTPM
- cerebral cortex: 62 nTPM
- adrenal gland: 59 nTPM
- skeletal muscle: 50 nTPM
- tonsil: 47 nTPM
Single-cell type
- megakaryocyte progenitors: 143 nCPM
- cone photoreceptor cells: 141 nCPM
- adrenal cortex cells: 137 nCPM
- alveolar cells type 2: 128 nCPM
- megakaryocyte-erythroid progenitors: 122 nCPM
- nk-cells: 105 nCPM
Immune cell
- NK-cell: 97 nTPM
- gdT-cell: 58 nTPM
- MAIT T-cell: 58 nTPM
- basophil: 54 nTPM
- memory CD8 T-cell: 54 nTPM
- total PBMC: 51 nTPM
Brain region
- basal ganglia: 75 nTPM
- cerebral cortex: 71 nTPM
- white matter: 70 nTPM
- hypothalamus: 67 nTPM
- thalamus: 61 nTPM
- pons: 58 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about YARS1.
Disease | AllUniProt
Conditions YARS1 is implicated in, by any mechanism.
- Charcot-Marie-Tooth disease, dominant intermediate C (CMTDIC) MIM:608323
- Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2 (IMNEPD2) MIM:619418
Disease | GeneticClinVar
15 pathogenic / likely-pathogenic of 656 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Charcot-Marie-Tooth disease dominant intermediate C
- Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset 2
- Charcot-Marie-Tooth disease
- Neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset
- Hepatic steatosis
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.62
- gnomAD pLI
- 0
- DepMap mean gene effect
- -1.95
- DepMap dependency class
- pan
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic process
- response to starvation
- tyrosyl-tRNA aminoacylation
Molecular functions
- ATP binding
- interleukin-8 receptor binding
- RNA binding
- small molecule binding
- tRNA binding
- tyrosine-tRNA ligase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of YARS1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads YARS1 as an antibody target. Whether an autoantibody or antibody against YARS1 could matter depends on whether native YARS1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
YARS1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label YARS1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...